NYSE · Healthcare · Drug Manufacturers - Specialty & Generic · Israel
Teva- Pharmaceutical Industries Ltd is a large cap company (market value between $10 billion and $200 billion) in the Drug Manufacturers - Specialty & Generic industry.
Intrinsic value, DCF valuation, financial health and value investing analysis for the Teva- Pharmaceutical Industries Ltd stock.
Overvalued: intrinsic value $20.57 per share, market price $39.52, margin of safety -92.1% (as of 2026-09-22).
Discounting its cash flows at 8.5% (average of 3 methods) values the shares at $20.57; the price of $39.52 is 92% above that value, and 77% of that value comes from beyond year five.
Leak Score: 0/100 on 3 of 12 signals (not enough of the checklist to rate).
All 84 Drug Manufacturers - Specialty & Generic stocks
20 more in this industry show a wider margin of safety.
TEVA is overvalued (as of the 2026-09-22 close). Discounting its cash flows at 8.5% (average of 3 methods) values the shares at $20.57; the price of $39.52 is 92% above that value, and 77% of that value comes from beyond year five.
$20.57 per share (as of the 2026-09-22 close), against a market price of $39.52. That is a margin of safety of -92.1%. The value is the average of the valuation methods that apply to this company, recomputed every night after the US close.
0 out of 100, on 3 of 12 value investing signals. Too much of the checklist is missing for a rating: the remaining signals need filings this company has not published yet, so treat the score as a partial read.